Completed
PHASE3
INTERVENTIONAL
NCT06323161
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study will look at how much CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participant will get either CagriSema or "dummy" medicine and which treatment they get is decided by chance. Participant will take the study medicine together with their current diabetes medicine (once-daily insulin with or without metformin). For each participant, the study will last for about one year.
Interventions
Name:
Cagrilintide
Type:
DRUG
Description:
Participants will receive once-weekly cagrilintide subcutaneously.
Name:
Semaglutide
Type:
DRUG
Description:
Participants will receive once-weekly semaglutide subcutaneously.
Name:
Placebo
Type:
DRUG
Description:
Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.
Primary Outcomes
Measure:
Change in Glycated Haemoglobin (HbA1c)
TimeFrame:
From baseline (week 0) to end of treatment (week 40)
Description:
Measured in percentage (%)- points.
Trial Information
NCT ID
NCT06323161
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025